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Summary WHT/Ht mice transplanted s.c. with NC carcinoma were treated with 16,16-dimethyl
prostaglandin E2 methyl ester (di-me-PGE2) and/or indomethacin. Each primary tumour was excised under
anaesthesia 3 weeks after transplantation, weighed and extracted for prostaglandins. Mouse survival time and
tumour recurrence were measured. Di-me-PGE2 lOg, injected at the tumour site on alternate days from day
1 to 19, indomethacin 2.5mgkg-1 daily by mouth, or both drugs together resulted in lighter tumours
(respectively 45, 45 and 52% less, n=18 to 20 per group, P<0.02) compared with vehicle-treated controls.
Indomethacin reduced the tumour prostaglandin yield, but the biological activity in extracts of tumours from
mice given di-me-PGE2 was high. The median survival time was longer in mice receiving indomethacin alone
(61 days from tumour transplantation compared with 50 days in controls P<0.02). Di-me-PGE2 alone had
little or no effect on survival (median 48 days) but counteracted the increase with indomethacin (di-me-
PGE2 +indomethacin, 49 days median survival). There were no obvious effects of the treatments on tumour
recurrence at the excision'site, but there was a higher incidence of involved lymph nodes in mice given di-me-
PGE2.
Several groups have reported apparently conflicting
findings on the effects of prostaglandins (PGs)
and/or their synthesis inhibitors on tumour weight
and mouse survival. In studies using a long-acting
analogue of PGE2 (16,16-dimethyl-PGE2 methyl
ester; di-me-PGE2) 5 or 10 pg per mouse daily, the
size of mouse B16 melanoma was smaller (Santoro
et al., 1976, 1977) and in some experiments host
survival time was longer (Santoro et al., 1977;
Favalli et al., 1980a). Other reports on the
beneficial effects of PGs on tumours include PGA1
and PGA2 (Honn et al., 1979; Favalli et al., 1980b),
PGD2 (Fitzpatrick & Stringfellow, 1979; Sakai et
al., 1984), PGF2a (Jubiz et al., 1979) and PGI2
(Honn et al., 1981).
In contrast, several groups have found that PG
synthesis inhibitors reduce mouse tumour weight
(Hial et al., 1976; Bennett et al., 1978, 1979, 1982;
Lynch et al., 1978; Lynch & Salomon, 1979;
Trevisani et al., 1980), and increase host survival
(Lynch et al., 1978; Bennett et al., 1978, 1979, 1982;
Trevisani et al., 1980). In a few studies PG
synthesis inhibitors were not of value, indicating
that different tumour types may vary in their
response (see Bennett, 1982).
The aim of the present study was to examine the
effect of PG administration on the beneficial
response to indomethacin in mice with NC
carcinoma. The supposition was made that if the
antitumour effect of indomethacin is due to
inhibition of PGE2 synthesis, then administration
of a PGE2 analogue would be likely to produce an
opposite response. We have therefore studied the
long-acting PGE2 analogue 16,16-dimethyl-PGE2
methyl ester (di-me-PGE2), given alone or together
with indomethacin, on the weight of the trans-
planted tumour and on the survival time of the
host mice.
Materials and methods
The NC carcinoma originally arose spontaneously
in the mammary region of a WHT/Ht mouse and
has been passaged since then in the same strain
(Hewitt et al., 1976). There is a high incidence of
local lymphatic spread and scar recurrence
following tumour excision, and metastasis occurs
mainly to the lungs and mediastinum.
On day 0, male WHT/Ht mice were injected s.c.
into the left flank with 106 NC carcinoma cells
prepared as described previously (Bennett et al.,
1979, 1982). There were 2 separate experiments
each vith 9 or 10 mice per group. Starting on day 1
each mouse received either 10 pg di-me-PGE2 (the
dose used by most of the previous investigators) on
alternate days until day 19 (several weeks before
the animals died), or 0.1 ml vehicle (150mM NaCI),
s.c. at the site of tumour transplantation. Body
weights were measured on day 0 (the day of
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Table I Effects of Di-me-PGE2 and/or indomethacin on tumour weight,
recurrence and mouse survival time
Indo +
Controls Di-me-PGE2 Indo Di-me-PGE2
Tumour 595 330b 330a 285C
wt (mg) (430-890) (220-490) (240-690) (180-340)
n=18 n=20 n=19 n=18
Tumour 39 660c Ila 71Ic
PG(ngg-) (30-48) (348-750) (5-23) (100-909)
n=10 n=10 n=10 n=9
Survival 50 48 61a.e 49d
(days) (47-51) (42-49) (49-63) (47-52)
n=18 n=19 n=19 n=19
Mice with scar
recurrence 11/18 12/19 10/19 13/19
Mice with lymph
node cancer 9/18 16/19f,g 7/19 15/199
Survival, measured from the time of tumour transplantation, was longer in
mice given indomethacin alone; this increase was counteracted by giving di-
me-PGE2. The superscripts represent probabilities, as follows:
ap<0.03.
bP<0.01.
cP<0.002, all compared to control group.
dp<O.003 compared to indomethacin group.
eP<0.0002 coinpared to di-me-PGE2 group.
There were no obvious differences in the numbers of mice with scar
recurrence, but more mice given the analogue with or without indomethacin
had involved lymph nodes.
fP=0.06 compared to vehicle controls (Fisher's exact test).
gP<0.02 compared to indomethacin alone (Fisher's exact test).
These results, and those of tumour weights and tumour PGs, are given as
medians with semiquartile ranges below in parentheses.
16,16-Dimethyl PGE2 (di-me-PGE2), 10,g per 0.1ml 150mM NaCl, was
injected s.c. into the area of tumour transplantation. Treatment started on
day 1 and was given on alternate days until day 19. Other groups received
0.1 ml saline alone. Daily oral administration of indomethacin (Indo,
2.5mgkg-1 in 50% syrup), or vehicle control (0.1 ml) began the day prior to
tumour transplantation and continued until the end of experiment. Tumours
were excised on day 21. The results are combined from 2 separate
experiments, except for tumour PGE2 measurements (Tumour PG, expressed
as ng PGE2 equivalentsg-1 tissue) which were made in only one experiment.
inoculation), and again on days 2, 6, 9, 13, 16 and
20. Each mouse was given indomethacin
(2.5mgkg-1) or vehicle (0.1 ml 50% syrup BP)
once daily by mouth from the day prior to tumour
transplantation and continued until death. Mice
with advanced carcinomatosis, or those who
survived for the duration of the experiment, were
killed humanely to prevent suffering. From
previous experience, the mice killed humanely
because of metastasis would have died within 24h
(see Bennett et al., 1982). Occasionally mice that
were not in distress in the evening died overnight.
The treatment groups are shown in Table I.
Transplanted tumours, excised under ether
anaesthesia on day 21, were weighed. In one
experiment they were homogenized in Krebs
solution, extracted (Unger et al., 1971) and
bioassayed on rat stomach strips for PGE2-like
activity (Bennett et al., 1973). Mouse survival time
was measured, and the incidences of scar
recurrence, lymph node involvement and distant
metastasis were noted at postmortem. Survival was
analysed statistically by the method of Lee & Desu
(1972), and the other data were analysed using the
Mann-Whitney U-test or, where specified, Fisher's
exact test.PROSTAGLANDINS AND CANCER 247
Results
The time for the transplanted tumours to become
established was similar in all groups (controls,
indomethacin, di-me-PGE2 and indomethacin+di-
me-PGE2). However, the tumours from treated
mice were lighter (Table I). Although the median
tumour weight was least when both indomethacin
and di-me-PGE2 were given together, the difference
compared with either drug alone was likely to have
arisen by chance (P>0.1).
The amounts of extracted prostaglandin-like
material (PG-LM) were lowest in tumours from the
indomethacin-treated mice (P<0.02 compared to
controls). Tumours from mice receiving di-me-
PGE2 alone or with indomethacin yielded high
amounts of biological activity (P<0.002 compared
to controls) and the extracts evoked contractions of
rat fundus that subsided more slowly than with
PGE2 or extracts of tumours from mice not given
the analogue. Di-me-PGE2 added to the bathing
fluid also caused a long-lasting contraction, and its
potency was 2 orders of magnitude more than that
of PGE2. These findings suggest that di-me-PGE2
in the tumour extracts may contribute to the
biological activity and, since the last dose was given
2 days before tumour excision, the half-life seems to
be long in these mice.
As shown in Table I, mice treated with indo-
methacin survived longer than controls (P<0.02).
With di-me-PGE2 alone there was, if anything, a
tendency to reduce survival (P<0.1). Furthermore,
the analogue counteracted the increase in survival
with indomethacin. There were no obvious effects
of treatment on tumour recurrence at the excision
site, but more mice given di-me-PGE2 had involved
lymph nodes than did controls or those given
indomethacin. On the day of treatment with the PG
analogue (alone or with indomethacin) the mice
were lethargic with laboured respiration; 2h after
the injection, diarrhoea occurred and lasted 6h.
However, in the several weeks after stopping
treatment with the analogue the mice appeared
normal until metastases had developed. The mean
weights of the mice in the 4 groups on the day of
tumour transplantation were 35.2-36.0g. By day
20, the day before tumour excision, the mean
weight of the control mice had increased by 5.4%,
compared with 0.8, 1.1 and 0.6% respectively in
those given di-me-PGE2, indomethacin, or both
drugs together.
Discussion
As in our previous work, indomethacin-treated
mice, with excised NC tumours lived longer than
controls (Bennett et al., 1982). The ability of di-me-
PGE2 to counteract this increase is evidence that
indomethacin acts via inhibition of PGE2
formation, rather than by its other properties
(Flower, 1974). This conclusion is strengthened by
the finding that flurbiprofen, a structurally
unrelated prostaglandin synthesis inhibitor, also
increases host survival (Bennett et al., 1982). PGE2
production by NC tumours may therefore con-
tribute to their malignancy, a conclusion that is
consistent with the higher incidence of involved
lymph nodes in mice given di-me-PGE2 compared
with those given vehicle or indomethacin. A
reduction of the transplanted tumour weight is
unlikely to contribute substantially to the increased
survival with indomethacin since treatment started
after tumour excision also lengthens survival
(Bennett et al., 1982). Furthermore, di-me-PGE2
also reduced tumour weight but, if anything, mouse
survival time was shorter. It therefore seems likely
that indomethacin acts by reducing the
development of metastases from transplanted NC
tumours, whereas the analogue may cause an
increase.
Toxic effects of drugs can influence the
development of cancer, but this seems unlikely to
explain the counteraction by the analogue of the
increased survival with indomethacin. The body
weights prior to tumour excision were similar in the
mice given di-me-PGE2 and/or indomethacin, and
thereafter all the animals looked healthy prior to
the development of metastases. Furthermore, others
who have used similar doses of the analogue in
mice claim that it increases survival in mice with B-
16 melanoma (Santoro et al., 1977; Favalli et al.,
1980a) and Friend erythroleukaemia (Santoro &
Jaffe, 1979).
These latter publications may indicate that the
response to di-me-PGE2 varies with the tumour
type, but in the 1977 study a longer survival with
the analogue occurred only in mice injected with
I05 B-16 melanoma cells, and not with 106 B-16
melanoma cells; the difference remains to be
substantiated and explained. Furthermore, with the
Friend erythroleukaemia the effect of di-me-PGE2
on mouse survival was small, and the rate of
tumour appearance was unaltered, except when the
injected cells were treated with dimethylsulphoxide
to increase their differentiation. None of these other
studies combined di-me-PGE2 with a PG synthesis
inhibitor.
Consistent with our mouse survival data, the rate
of appearance of transplanted NC tumours was not
affected by di-me-PGE2 and/or indomethacin. This
contrasts with the short delay of B16 melanoma
appearance in mice given di-me-PGE2 (Santoro et
al., 1977; Favalli et al., 1980a), and the slightly
faster development of palpable s.c. B16 melanoma
tumours with indomethacin (Favalli et al., 1980a).248 A. BENNETT et al.
However, the significance of the latter finding is not
clear since subsequent measurements of tumour
sizes and weights by these investigators were similar
in the treated mice and controls. Furthermore, in
another paper from this group B-16 melanomas
from indomethacin-treated mice were smaller and
lighter than controls (Hofer et al., 1980), which
accords with our findings with the NC tumour and
with other tumours studied by several different
groups (see Introduction).
Di-me-PGE2 is reported to increase PGE2
formation by Friend erythroleukaemia cells and B-
16 melanoma (Santoro et al., 1979; Favalli et al.,
1980a). The analogue therefore appears to have a
complex action involving an effect on arachidonate
release and/or metabolism, as well as stimulation of
PGE2 receptors. It is possible that stimulation of
PG formation helps explain the increased amount
of biological activity extracted from tumours of our
mice, but this seems unlikely to be the main
explanation since there was very high activity in
extracted tumours from mice also given indo-
methacin, and the shape of the assay tissue
response differed from that to PGE2. A more likely
explanation is that some of the administered
analogue remained in the excised tissues and contri-
buted to the biological activity.
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